CN112094317A - His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 - Google Patents
His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 Download PDFInfo
- Publication number
- CN112094317A CN112094317A CN201910527878.3A CN201910527878A CN112094317A CN 112094317 A CN112094317 A CN 112094317A CN 201910527878 A CN201910527878 A CN 201910527878A CN 112094317 A CN112094317 A CN 112094317A
- Authority
- CN
- China
- Prior art keywords
- gly
- lys
- obzl
- cbz
- trt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 His-Gly-Lys modified methotrexate Chemical class 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 title abstract description 21
- 238000012546 transfer Methods 0.000 title description 3
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 10
- 229960000485 methotrexate Drugs 0.000 claims description 9
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 23
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000004709 cell invasion Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- PMJARSVDFGNNRI-UHFFFAOYSA-N dichloromethane;piperidine Chemical compound ClCCl.C1CCNCC1 PMJARSVDFGNNRI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了下面通式的His‑Gly‑Lys修饰的甲氨蝶呤(式中R1为His‑Gly‑Lys时R2为OH,R1为OH时R2为His‑Gly‑Lys,以及R1和R2同时为His‑Gly‑Lys),公开了它们的制备方法,公开了它们对肿瘤转移的抑制作用。因而本发明公开了它们在制备抗肿瘤转移药物中的应用。
Description
技术领域
本发明涉及His-Gly-Lys修饰的甲氨蝶呤,涉及它们的制备方法,涉及它们的抗肿瘤转移作用。因而本发明涉及它们在制备抗肿瘤转移药物中的应用。本发明属于生物医药领域。
背景技术
癌症是指细胞不受控制以及不正常的增殖,并有机会通过机体血液系统或者淋巴系统向其它部位扩散转移的的一类疾病,是世界性的重大医学难关。据国家癌症中心2019年初发布的我国2015年各地区恶性肿瘤发病以及死亡数据结果显示,白血病位列死亡率最高的恶性肿瘤前十位。作为最早用于治疗急性白血病的药物之一,甲氨蝶呤已有70余年临床应用史。可是,骨髓毒性,肝毒性,肾毒性,口腔粘膜副作用以及耐药性严重限制了甲氨蝶呤的应用及疗效。发明人在一份申请书中描述了用His-Gly-Lys修饰甲氨蝶呤得到的下面通式的His-Gly-Lys-甲氨蝶呤(式中R1为His-Gly-Lys时R2为OH,R1为OH时R2为His-Gly-Lys,以及R1和R2同时为His-Gly-Lys)可克服这些问题的发明。本案进一步描述His-Gly-Lys-甲氨蝶呤意外地具有抗肿瘤转移活性。根据这个意外的发现,发明人提出了本发明。
发明内容
本发明的第一个内容是提供下面通式的His-Gly-Lys修饰的甲氨蝶呤(式中R1为His-Gly-Lys时R2为OH,R1为OH时R2为His-Gly-Lys,以及R1和R2同时为His-Gly-Lys)。
本发明的第二个内容是提供His-Gly-Lys修饰的甲氨蝶呤的制备方法，该方法包括：
1采用二环己基碳二亚胺为缩合剂,N-羟基苯并三氮唑为催化剂,液相合成Fmoc-His(Trt)-Gly-Lys(Cbz)-OBzl；
2脱除Fmoc合成His(Trt)-Gly-Lys(Cbz)-OBzl；
3采用二环己基碳二亚胺为缩合剂,N-羟基苯并三氮唑为催化剂,将甲氨蝶呤与His(Trt)-Gly-Lys(Cbz)-OBzl偶联生成如下通式的His(Trt)-Gly-Lys(Cbz)-OBzl修饰的甲氨蝶呤,式中R1’为His(Trt)-Gly-Lys(Cbz)-OBzl时R2’为OH,R1’为OH时R2’为His(Trt)-Gly-Lys(Cbz)-OBzl,以及R1’和R2’同时为His(Trt)-Gly-Lys(Cbz)-OBzl；
4在酸性条件下脱除保护基生成下面通式的His-Gly-Lys修饰的甲氨蝶呤(式中R1为His-Gly-Lys时R2为OH,R1为OH时R2为His-Gly-Lys,以及R1和R2同时为His-Gly-Lys)。
本发明的第三个内容是评价上面通式的His-Gly-Lys修饰的甲氨蝶呤的抑制肿瘤转移活性。
附图说明
图1His-Gly-Lys修饰的甲氨蝶呤的合成路线。(ⅰ)无水四氢呋喃,二环己基碳二亚胺,N-羟基苯并三氮唑,N-甲基吗啉；(ⅱ)氯化氢的乙酸乙酯溶液；(ⅲ)20％哌啶的二氯甲烷溶液；(ⅳ)无水N,N-二甲基甲酰胺,二环己基碳二亚胺,N-羟基苯并三氮唑,N-甲基吗啉；(ⅴ)三氟乙酸/三氟甲磺酸。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备Boc-Gly-Lys(Cbz)-OBzl(1)
用60mL无水四氢呋喃溶解1.02g(5.81mmol)Boc-Gly,得到1号溶液。0℃与搅拌下,将1.43g(6.98mmol)二环己基碳二亚胺和0.79g(5.85mmol)N-羟基苯并三唑的无水四氢呋喃溶液加入到1号溶液中搅拌30分钟。随后加入2.35g(5.78mmol)HCl·Lys(Cbz)-OBzl,用N-甲基吗啉调节反应液pH至9,移去冰浴,在室温下充分搅拌17小时后TLC(二氯甲烷/甲醇＝30/1)显示反应完成,终止反应。过滤,浓缩,残留物用100mL乙酸乙酯溶解,溶液依次分别用饱和碳酸氢钠水溶液洗(30mL×3),饱和氯化钠水溶液洗(30mL×3),5％硫酸氢钾水溶液洗(30mL×3),饱和氯化钠水溶液洗(30mL×3),饱和碳酸氢钠水溶液洗(30mL×3),饱和氯化钠水溶液洗(30mL×3)。得到的乙酸乙酯相用无水硫酸钠干燥12小时,过滤,浓缩,得到3.05g(100％)目标化合物,为黄色油状物。ESI-MS(m/e):528[M+H]+。
实施例2制备Gly-Lys(Cbz)-OBzl(2)
将1.75g(3.32mmol)化合物(1)用无水乙酸乙酯溶解。0℃与搅拌下,加入20mL氯化氢的乙酸乙酯溶液(4M),搅拌9小时后TLC(二氯甲烷/甲醇＝30/1)点板显示反应完成。温水浴条件下,反复减压浓缩反应液,随后用无水酸乙酯溶解浓缩物,重复减压浓缩反应液(3次),再用无水乙醚反复磨洗反应物,得到1.40g(98％)目标化合物，为黄色粘稠油状物。ESI-MS(m/e):428[M+H]+。
实施例3制备Fmoc-His(Trt)-Gly-Lys(Cbz)-OBzl(3)
采用实施例1的方法,从1.87g(3.02mmol)Fmoc-His(Trt)和1.40g(3.02mmol)化合物(2)中得到2.02g(65％)目标化合物,为无色粉末。ESI+MS(m/e):1029[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.20(t,J＝5.4Hz,1H),7.90(s,1H),7.88(s,1H),7.68-7.64(m,2H),7.43-7.20(m,27H),7.06-7.03(m,6H),6.73(s,1H),5.12(s,1H),5.07(s,2H),5.00-4.99(m,2H),4.30-4.12(m,4H),3.75-3.67(m,2H),2.97-2.89(m,3H),2.83-2.74(m,1H),1.68-1.55(m,2H),1.38-1.24(m,4H)。
实施例4制备His(Trt)-Gly-Lys(Cbz)-OBzl(4)
用20mL 20％哌啶二氯甲烷溶液溶解1.80g(1.75mmol)化合物(3),0℃与搅拌下,搅拌6小时后TLC(二氯甲烷/甲醇＝20/1)显示反应完成,终止反应。在25℃水浴条件下,浓缩,得到白色固体,加入石油醚反复磨洗反应物,同样用无水乙醚磨洗三次,经减压硅胶柱层析纯化,得到0.83g(59％)目标化合物,为无色粉末。ESI+MS(m/e):807[M+H]+，1H NMR(300MHz,DMSO-d6):δ/ppm＝8.69(d,J＝7.5Hz,1H),8.17(s,1H),7.40-7.24(m,21H),7.08-7.06(m,6H),6.68(s,1H),5.04(s,2H),4.99(s,2H),4.32-4.38(m,1H),3.79-3.65(m,2H),3.42-3.41(m,1H),2.92(d,J＝5.7Hz,2H),2.80-2.64(m,2H),1.66-1.56(m,2H),1.31-1.24(m,4H)。
实施例5制备His(Trt)-Gly-Lys(Cbz)-OBzl修饰的甲氨蝶呤(1a,1b,1c)
用40mL无水N,N-二甲基甲酰胺溶解0.47g(1.03mmol)甲氨蝶呤,得到1号溶液。0℃与搅拌下,将0.26g(1.26mmol)二环己基碳二亚胺和0.14g(1.14mmol)N-羟基苯并三唑无水的N,N-二甲基甲酰胺溶液加入到1号溶液中,搅拌30分钟。加入0.83g(1.03mmol)化合物(4),用N-甲基吗啉调节反应液pH至9,移除冰浴,在室温下充分搅拌8小时后TLC(乙酸乙酯/水/冰醋酸＝6/1/1)显示反应完成,过滤除去不溶白色固体二环己基脲,将滤液减压旋除溶剂,经制备薄层析分离纯化(乙酸乙酯/水/冰醋酸＝6/1/1)得到0.27g(21％)化合物1a,0.66g(63.63％)化合物1b和0.12g(10％)化合物1c。它们的结构如下：
1a为橘黄色粉末,ESI-MS(m/e):1241[M-H]-,1H NMR(300MHz,DMSO-d6):δ/ppm＝11.98(s,1H),8.53(s,1H),8.36-8.15(m,3H),7.69(m,2H),7.32(m,22H),7.02(s,7H),6.70-6.63(m,5H),5.05(s,2H),4.98(s,2H),4.75(s,2H),4.39(m,1H),4.27-4.25(m,2H),3.74-3.51(m,2H),3.17(s,3H),2.89-2.85(m,4H),2.37(m,1H),2.28(m,1H),1.60-1.48(m,4H),1.32-1.24(m,4H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝173.41,172.24,171.70,128.49,128.46,128.28,169.45,163.33,163.16,162.79,156.52,155.67,151.23,149.47,146.36,142.65,142.63,142.54,137.74,136.40,129.70,129.64,129.57,128.86,128.77,128.60,128.57,128.49,128.46,128.40,128.35,128.28,128.24,128.14,128.10,127.99,121.93,121.67,119.36,111.44,111.28,74.89,66.21,66.17,65.54,52.44,47.97,42.57,40.57,31.24,30.90,30.85,29.38,25.96,24.56。
1b为橘黄色粉末,Q-TOF-MS(m/e):2031[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.52(d,J＝2.7Hz,1H),8.44-8.37(m,2H),8.29-8.18(m,3H),7.69-7.61(m,2H),7.31-7.26(m,41H),7.22-7.20(m,2H),7.04-7.02(m,13H),6.73-6.61(m,6H),5.05(m,4H),4.98(s,4H),4.74(s,2H),4.54-4.38(m,1H),4.25(m,2H),4.12(m,2H),3.75-3.54(m,4H),3.15(s,3H),2.90-2.74(m,8H),2.27-2.02(m,2H),1.63-1.41(m,6H),1.24-0.98(m,8H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝172.33,172.27,172.18,172.07,171.67,171.64,169.51,169.47,169.41,169.27,167.24,163.33,163.17,162.78,156.52,155.67,151.33.149.51,146.42,146.39,142.57,142.52,137.73,136.70,136.36,129.67,129.51,128.86,128.84,128.77,128.59,128.56,128.51,128.42,128.39,128.34,128.24,128.15,127.98,127.79,127.10,127.06,126.87,126.85,121.92,121.50,119.95,119.94,111.29,111.26,89.29,66.28,66.24,55.35,53.26,52.36,47.97,42.45,40.59,40.43,40.26,36.25,33.82,31.24,31.00,30.98,30.94,29.35,27.38,22.93,22.79。
1c为橘黄色粉末,ESI-MS(m/e):1243[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.56(s,1H),8.41(m,1H),7.82-7.80(m,2H),7.64(m,3H),7.32(m,21H),7.05-7.03(m,6H),6.82-6.80(d,J＝7.2Hz,2H),6.70(s,1H),6.60(s,2H),5.06(s,2H),4.98(s,2H),4.76(s,2H),4.40(m,1H),4.23-4.11(m,5H),3.68(m,2H),3.18(s,3H),2.15(m,2H),1.86(m,2H),1.63(m,2H),1.31-1.24(m,4H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝173.16,173.36,172.27,172.23,169.83,169.72,163.31,163.17,162.80,156.54,155.65,151.16,149.59,146.47,142.62,137.77,136.42,129.66,128.87,128.77,128.68,128.61,128.40,128.13,128.11,122.65,122.57,121.90,119.90,111.69,74.97,66.21,66.18,55.35,53.54,53.44,52.47,47.97,42.76,40.56,33.81,32.61,32.20,31.25,25.79,22.95。
实施例6制备结构式如下的His-Gly-Lys修饰甲氨蝶呤α羧基(2a)
称取0.12g(0.095mmol)化合物1a,0℃与搅拌下,先缓慢加入2mL三氟乙酸，再加入0.6mL三氟甲磺酸,搅拌40分钟后,0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟。随即加入冰乙醚30mL,析出橘黄色不溶物，静置,弃除上清,重复3次。用少量水溶解反应物,再用稀氨水调节溶液pH＝8,经C18柱层析纯化,收集洗脱液,将收集液在-80℃低温预冻,冷冻干燥机冻干样品,得到0.032g(44％)化合物2a,为橘黄色粉末。ESI-MS(m/e):775[M-H]-,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.60(d,J＝3.3Hz,1H),8.45(s,1H),8.32-8.11(m,5H),7.96(s,1H),7.76-7.71(m,2H),7.64(s,1H),7.23(s,1H),7.16(s,1H),7.06(s,1H),6.83-6.81(m,2H),4.82(s,2H),4.52(m,1H),4.31(m,1H),4.20(m,1H),3.84-3.65(m,2H),3.23(s,3H),3.12-2.93(m,2H),2.75(m,2H),2.27-2.25(m,1H),2.20-2.13(m,1H),1.90-1.87(m,2H),1.73-1.69(m,1H),1.64-1.50(m,3H),1.34-1.18(m,2H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝174.55,174.43,173.84,172.47,172.34,170.94,169.35,169.23,167.19,163.17,160.81,151.43,149.43,148.43,148.32,134.51,129.57,122.45,122.20,121.42,119.89,117.32,111.56,55.32,53.75,53.57,52.47,52.10,42.46,42.46,42.34,30.95,30.78,27.93,26.94,22.69。
实施例7制备结构式如下的His-Gly-Lys修饰甲氨蝶呤α,γ羧基(2b)
称取0.18g(0.089mmol)化合物1b,0℃与搅拌下,先缓慢加入2mL三氟乙酸,再加入0.6mL三氟甲磺酸,搅拌40分钟后,终止反应。0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟。随即加入冰乙醚30mL,析出橘黄色不溶物,静置,弃除上清,重复3次,用少量水溶解反应物,再用稀氨水调节溶液pH＝8,经C18柱层析纯化,收集洗脱液。在-80℃低温预冻,冷冻干燥机冻干样品,得到0.036g(37％)化合物2b,为橘黄色粉末。ESI-MS(m/e):1099[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.57(s,1H),8.32-8.26(m,8H),8.10(d,J＝7.5Hz,2H),7.88(s,2H),7.75-7.64(m,7H),7.18-7.03(m,4H),6.81(d,J＝8.4Hz,2H),4.83(s,2H),4.53-4.51(m,2H),4.20(m,3H),3.83-3.66(m,4H),3.24(s,3H),3.03-2.87(m,4H),2.76(m,4H),2.16(m,2H),1.91-1.72(m,4H),1.60-1.49(m,6H),1.33(m,4H)；13C NMR(75MHz,DMSO-d6):δ/ppm＝173.94,173.88,173.84,172.50,172.29,171.37,171.12,169.33,169.23,167.15,163.18,161.45,151.42,149.41,147.87,134.84,134.63,131.33,131.19,129.55,127.58,123.30,122.14,121.52,121.38,119.03,117.54,111.57,55.33,53.73,52.78,52.57,52.17,42.51,42.47,42.35,41.13,32.29,28.35,28.31,27.36,27.33,27.31,27.27,27.00,22.73。
实施例8制备结构式如下His-Gly-Lys修饰甲氨蝶呤γ羧基(2c)
称取0.11g(0.087mmol)化合物1c,0℃与搅拌下,先缓慢加入1mL三氟乙酸,再加入0.3mL三氟甲磺酸,搅拌40分钟后,终止反应。0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟,随即加入30mL冰乙醚,析出橘黄色不溶物,静置,弃除上清,重复3次。用少量水溶解反应物,再用稀氨水调节溶液pH＝7-8,经C18柱层析纯化,收集洗脱液,将收集液在-80℃低温预冻,冷冻干燥机冻干样品,得到0.017g(25％)化合物2c,为橘黄色粉末。ESI-MS(m/e):775[M-H]-,1H NMR(500MHz,DMSO-d6/D2O＝10/1):δ/ppm＝8.59(s,1H),7.83(d,J＝10.5Hz,1H),7.69(d,J＝8.0Hz,2H),6.96(d,J＝3Hz,1H),6.84(d,J＝9.0Hz,2H),4.82(s,2H),4.42-4.40(m,1H),4.08(m,1H),3.81-3.77(m,1H),3.70-3.65(m,1H),3.22(s,3H),3.04-3.01(m,1H),2.89-2.88(m,1H),2.79-2.78(m,2H),2.21(m,2H),2.02-2.00(m,1H),1.89-1.85(m,1H),1.74-1.73(m,1H),1.62-1.53(m,3H),1.27(m,2H)；13C NMR(125MHz,DMSO-d6/D2O＝10/1):δ/ppm＝175.67,175.59,175.50,175.40,174.07,172.57,169.31,166.97,162.98,162.28,154.18,151.45,149.62,147.84,134.99,132.42,129.06,121.86,121.21,117.39,111.78,55.33,54.45,54.37,53.66,52.96,43.00,42.95,31.15,29.05,27.27,27.22,22.86。
实验例1测定化合物2a-c的体外抗肿瘤细胞迁移作用
1)化合物2a-c用无胎牛血清培养基配制成所需浓度。
2)肿瘤细胞为A549(人非小细胞肺癌细胞)。
3)将生长状态良好,处于对数生长期的A549细胞按照5×106个/mL的密度使用无血清的培养基接种在Transwell的上室,每室加入100μL,加入化合物2a-c(终浓度分别为1,0.5,0.5μM)。同时在下室加入600μL含有10％胎牛血清的培养基,将Transwell小室放入24孔培养板中,于37℃的5％二氧化碳培养箱中孵育7小时,用棉签拭去上室的细胞,吸弃下室的培养基,用4％多聚甲醛固定液固定细胞30分钟,弃固定液,用PBS洗2次,用结晶紫染色15分钟,清水洗去浮色,显微镜观察。随机选取6个不同的视野观察细胞并计算迁移数。结果见表1,数据经t检验。可以确认,在IC10浓度下化合物2a-c有效地抑制肿瘤细胞迁移。此外,它们的抗A549细胞迁移活性与20μM浓度下Arg-Gly-Asp-Ser(RGDS)无显著性差异。这是本发明的突出的技术效果。
表1化合物2a-c抑制A549细胞迁移活性
a)与PBS组相比,P<0.01；b)与PBS组相比,P<0.01,与RGDS组相比,P>0.05；n＝6。
实验例2化合物2a-c抑制肿瘤细胞侵袭活性
1)化合物2a-c用无胎牛血清培养基配制成所需浓度。
2)肿瘤细胞为A549(人非小细胞肺癌细胞)。
3)标准型基底膜胶Matrigel用无血清的培养基稀释10倍,37℃沉降12小时,弃上清液。
4)将生长状态良好,处于对数生长期的A549细胞按照1×107个/mL的密度使用无血清的培养基接种在Transwell的上室,每室加入100μL,加入化合物2a-c(终浓度分别为1,0.5,0.5μM),同时在下室加入600μL含有10％胎牛血清的培养基,将Transwell小室放入24孔培养板中,37℃的5％二氧化碳培养箱中孵育12小时。用棉签拭去上室的细胞,弃下室的培养基,用4％多聚甲醛固定液固定细胞30分钟,弃固定液,用PBS洗2次,用结晶紫染色15分钟，清水洗去浮色,用显微镜观察。随机选取6个不同的视野观察细胞并计算侵袭数。结果见表2,数据经t检验。可以看到,在IC10浓度下化合物2a-c能有效地抑制肿瘤细胞侵袭,其中,2a抗A549细胞侵袭活性与20μM浓度下Arg-Gly-Asp-Ser(RGDS)的活性有差异,优于RGDS。2b,2c抗A549细胞侵袭活性与20μM浓度下RGDS无差异,活性相当。这是本发明的突出的技术效果。
表2化合物2a-c抑制A549细胞侵袭活性
a)与PBS组相比,P<0.01；b)与PBS组相比,P<0.01,与RGDS组相比,P<0.05；c)与PBS组相比,P<0.05；d)与RGDS组相比,P>0.05；n＝6。
实验例3化合物2a-c抑制肿瘤肺转移活性
将化合物2a-c溶于生理盐水。Lewis小鼠肺癌细胞(LLC,购自ATCC)用含有10％FBS和1×105U·L-1青霉素和100mg·L-1链霉素的DMEM培养基培养。每天传代一次,富集细胞。待细胞处于对数生长期且生长状态良好时消化细胞。用生理盐水调整细胞密度至2×107个/mL。
体重为20±2g的近交系C57BL/6雄性小鼠用左手固定,用75％乙醇涂在小鼠右前肢腋窝皮肤处消毒,右手以1mL无菌注射器于消毒皮下处注射肿瘤细胞悬液,每只注射0.2mL,取接种10天生长状态良好的Lewis肺癌荷瘤小鼠,乙醚麻醉后颈椎脱臼处死。用75％乙醇浸泡消毒10min,在超净台上操作剥离瘤体,选择生长良好的肿瘤组织,在无菌培养皿中剪碎,放置于玻璃组织匀浆器中研磨。研磨时按照瘤块重量(g)/生理盐水体积(mL)为1/3的比例加4℃预冷的生理盐水。研磨制得的细胞悬液用200目的尼龙网过滤,收集的细胞用生理盐水调浓度为2×107个/mL。取体重为20±2g的近交系C57BL/6雄性小鼠,左手固定小鼠,用75％乙醇涂在小鼠右前肢腋窝皮肤处消毒,右手以1mL无菌注射器于消毒皮下处注射肿瘤细胞悬液,每只注射0.2mL,接种后10天可以长成绿豆大小的肿瘤。测量肿瘤体积,肿瘤直径为4-6mm的小鼠随机分组。化合物2a-c组小鼠连续腹腔注射给药10天，剂量为0.033μmol/kg/天。以Arg-Gly-Asp-Ser(RGDS,剂量为20μmol/kg/天)作阳性对照。空白组小鼠每日腹腔注射0.2mL/只/天生理盐水。给药第11天称小鼠体重,乙醚麻醉,剖取各组小鼠的肺计算转移的瘤节数,并剖取各组小鼠的肿瘤称重。结果见表3,数据经t检验。可以看到,当2a-c的给药剂量降至Glu-Asp-Gly的1％时,2a-c仍表现出与His-Gly-Lys和RGDS无统计学差异的体内抗肿瘤转移活性,具有良好的体内抗Lewis肺癌向小鼠肺部转移活性,可见本发明化合物2a-c具有显著的技术效果。
表3化合物2a-c抑制肿瘤肺转移活性
注：n＝11；a)与生理盐水组相比P<0.01；b)与生理盐水组相比P<0.01,与RGDS组相比P>0.05,与His-Gly-Lys组相比P>0.05。
Claims (3)
1.如下通式的His-Gly-Lys修饰的甲氨蝶呤,
式中R1为His-Gly-Lys时R2为OH,R1为OH时R2为His-Gly-Lys,以及R1和R2同时为His-Gly-Lys。
2.权利要求1的His-Gly-Lys修饰的甲氨蝶呤的制备方法,该方法包括:
2.1采用二环己基碳二亚胺为缩合剂,N-羟基苯并三唑为催化剂,液相合成Fmoc-His(Trt)-Gly-Lys(Cbz)-OBzl；
2.2脱除Fmoc合成His(Trt)-Gly-Lys(Cbz)-OBzl；
2.3采用二环己基碳二亚胺为缩合剂,N-羟基苯并三唑为催化剂,将甲氨蝶呤与His(Trt)-Gly-Lys(Cbz)-OBzl偶联生成如下通式的His(Trt)-Gly-Lys(Cbz)-OBzl修饰的甲氨蝶呤,式中R1’为His(Trt)-Gly-Lys(Cbz)-OBzl时R2’为OH,R1’为OH时R2’为His(Trt)-Gly-Lys(Cbz)-OBzl,以及R1’和R2’同时为His(Trt)-Gly-Lys(Cbz)-OBzl；
2.4在酸性条件下脱除保护基生成权利要求书1的His-Gly-Lys修饰的甲氨蝶呤。
3.权利要求1的His-Gly-Lys修饰的甲氨蝶呤在制备抗肿瘤转移药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910527878.3A CN112094317B (zh) | 2019-06-18 | 2019-06-18 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910527878.3A CN112094317B (zh) | 2019-06-18 | 2019-06-18 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112094317A true CN112094317A (zh) | 2020-12-18 |
| CN112094317B CN112094317B (zh) | 2022-04-22 |
Family
ID=73749217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910527878.3A Expired - Fee Related CN112094317B (zh) | 2019-06-18 | 2019-06-18 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112094317B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112094322A (zh) * | 2019-06-18 | 2020-12-18 | 首都医科大学 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101072566A (zh) * | 2004-11-03 | 2007-11-14 | 为人技术株式会社 | 用于经皮给药的药物组合物 |
| CN104371009A (zh) * | 2014-06-24 | 2015-02-25 | 上海市计划生育科学研究所 | GnRH多肽-甲氨蝶呤偶联物、其制备方法及用途 |
| CN105879040A (zh) * | 2014-10-27 | 2016-08-24 | 彭师奇 | 聚天冬酰-rgdf-抗肿瘤药物复合物的制备和应用 |
| CN107684627A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | 介孔二氧化硅‑甲氨蝶呤‑米托蒽醌纳米粒,其制备，活性及应用 |
| WO2018208125A1 (ko) * | 2017-05-11 | 2018-11-15 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
-
2019
- 2019-06-18 CN CN201910527878.3A patent/CN112094317B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101072566A (zh) * | 2004-11-03 | 2007-11-14 | 为人技术株式会社 | 用于经皮给药的药物组合物 |
| CN104371009A (zh) * | 2014-06-24 | 2015-02-25 | 上海市计划生育科学研究所 | GnRH多肽-甲氨蝶呤偶联物、其制备方法及用途 |
| CN105879040A (zh) * | 2014-10-27 | 2016-08-24 | 彭师奇 | 聚天冬酰-rgdf-抗肿瘤药物复合物的制备和应用 |
| CN107684627A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | 介孔二氧化硅‑甲氨蝶呤‑米托蒽醌纳米粒,其制备，活性及应用 |
| WO2018208125A1 (ko) * | 2017-05-11 | 2018-11-15 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
Non-Patent Citations (4)
| Title |
|---|
| MARIA LINDGREN等: "Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide", 《BIOCHEMICAL PHARMACOLOGY》 * |
| MASAYASU KAWASAKI等: "Effect of His-Gly-Lys Motif Derived from Domain 5 of High Molecular Weight Kininogen on Suppression of Cancer Metastasis Both in Vitro and in Vivo", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| 吴学萍等: "短肽修饰的甲氨蝶呤的制备及细胞毒性作用", 《中国医院药学杂志》 * |
| 徐秀月等: "HKa 轻链D5 区及其合成肽对MDA-MB-231 细胞增殖和凋亡的影响", 《中国医科大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112094322A (zh) * | 2019-06-18 | 2020-12-18 | 首都医科大学 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用 |
| CN112094322B (zh) * | 2019-06-18 | 2022-04-22 | 首都医科大学 | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112094317B (zh) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104530199A (zh) | 一种抗肿瘤多肽及其制备方法和应用 | |
| CN112094317B (zh) | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用 | |
| CN108976159B (zh) | 芳香氨基酸修饰的吲哚乙醇衍生物，其合成，活性和应用 | |
| CN112094321B (zh) | His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用 | |
| CN101153053B (zh) | 骨生肽、其制备方法和其药物组合物与用途 | |
| CN100381459C (zh) | 阿霉素的衍生物及其制备方法和用途 | |
| CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
| CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
| CN110551121B (zh) | 谷氨酰胺酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用 | |
| CN112300246B (zh) | 天冬酰茶氨酸rgds修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN112094319B (zh) | Glu-Asp-Gly修饰的甲氨蝶呤,其合成,抗转移活性和应用 | |
| CN112390854B (zh) | 茶氨酸与rgds共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN112300244B (zh) | 茶氨酸单独及与rgds共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN112094322B (zh) | His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用 | |
| CN112110987B (zh) | 天冬胺酰茶氨酸苯丙氨酸修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN112300245B (zh) | Rgds和茶氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN112898376B (zh) | 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK,其制备,抗肿瘤活性和应用 | |
| CN112979750B (zh) | 二氧六环修饰的四氢咔啉-3-甲酰-The-EDG、其制备、抗转移活性和应用 | |
| CN110551120B (zh) | 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用 | |
| CN112010811B (zh) | 茶氨酸与苯丙氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
| CN108929320A (zh) | 3r-吲哚甲基-6r-恶唑烷酮修饰的哌嗪-2,5-二酮，其合成，活性和应用 | |
| CN112898379B (zh) | 二氧六环修饰的四氢咔啉-3-甲酰-The-HGE、其制备、抗肿瘤活性和应用 | |
| CN108976204B (zh) | 3s-吲哚甲基-6r-天冬氨酸修饰的哌嗪-2,5-二酮，其合成，活性和应用 | |
| CN108947979B (zh) | 3r-吲哚甲基-6r-极性氨基酸修饰的哌嗪-2,5-二酮，其合成，活性和应用 | |
| RU2142958C1 (ru) | Пептид, обладающий иммуномодулирующей активностью, и препарат на его основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220422 |